Loading organizations...
§ Private Profile · Belgium, WI, USA
Biotechnology company developing novel biotherapeutics via its Pept-in™ platform, targeting infectious diseases and oncology.
Aelin Therapeutics is a biopharmaceutical company based in Leuven, Belgium, that develops novel drugs using a proprietary platform to induce targeted protein aggregation for disabling disease-causing proteins. The biotechnology firm utilizes its Pept-in technology to create new classes of antibiotics and targeted treatments for severe infectious diseases and various oncology targets. The enterprise has secured $31.86 million in total equity funding to date, which includes a €27 million Series A financing round to advance its preclinical pipeline. The company is backed by a syndicate of prominent institutional investors, including Novartis Venture Fund, Boehringer Ingelheim Venture Fund, and Life Sciences Partners. Aelin Therapeutics was founded in 2017 as a spin-off from the Flanders Institute for Biotechnology, KU Leuven, Vrije Universiteit Brussel, and Ghent University, based on the scientific research of founders Joost Schymkowitz and Frederic Rousseau.
Aelin Therapeutics has raised $31.8M across 1 funding round.
Aelin Therapeutics has raised $31.8M in total across 1 funding round.
Aelin Therapeutics has raised $31.8M across 1 funding round. Most recently, it raised $31.8M Series A in December 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 11, 2017 | $31.8M Series A | — | Boehringer Ingelheim, Fund+, John DE Koning, Novartis, PMV | Announced |
Aelin Therapeutics has raised $31.8M in total across 1 funding round.
Aelin Therapeutics's investors include Boehringer Ingelheim, Fund+, John de Koning, Novartis, PMV.